Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back
Session Evaluation

CSVM

VASCULAR

CORONARY ARTERY DISEASE - GENERAL

EARLY CAREER INVOLVEMENT

351 - WHEN CHEST PAIN ISN'T ANGINA: ZEBRAS, UNICORNS AND THE WEIRD AND WONDERFUL!

Saturday, October 26, 2024
3:15 PM – 4:15 PM PT
Room: 114-115
Early Career Involvement
Workshop Description: Large vessel vasculitis is an uncommon but important vascular cause of chest pain which is challenging to diagnose and manage. Timely and appropriate management requires a multidisciplinary approach to patient care incorporating team-based principles. This session aims to bring together a multidisciplinary team to discuss strategies to consider when a patient with vasculitis presents to the cardiovascular team.

Interactive and Engagement Activities Description: The session will incorporate 3 short interactive presentations guided by cases to enhance participation and interactivity.
Q&A period will be dedicated to answering specific questions, and hosted by the panelists.

Learning Objectives:

At the end of this session participants will be able to:
  • When to think of large vessel vasculitis as a potential cause of chest pain and vascular disease
  • How to approach management of acute vascular inflammatory disease
  • How to approach long term follow-up and surveillance of prior vascular inflammation
  • How to incorporate multi-modality and multi-specialty imaging and diagnostics in complex vascular disease
Disclosure(s):
Sonia S. Anand, MD, PhD, FRCPC: Bayer AG: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Daiichi Sankyo: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Janssen Pharmaceuticals: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); novartis: speaker (Ongoing); Novonordisk: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)
Darryl Wan, MD, FRCPC, RPVI: Amgen: Honoraria (Ongoing); HLS Therapeutics: Advisory Board (Ongoing), Honoraria (Ongoing); Novartis: Advisory Board (Ongoing); Novo Nordisk: Advisory Board (Ongoing); Sanofi: Honoraria (Ongoing); Ultragenyx: Advisory Board (Ongoing)
Paula J. Harvey, BMBS, PhD, FRACP: Abbvie: honoraria for CME talk on Rheumatic Diseases and cardiovascular risk (Terminated, May 31, 2023); UPharmacy conferenc, BIOS supported the session: honoraria for CME talk on Women's Cardiovascular Health (Terminated, April 1, 2023)
Nader A. Khalidi: AbbVie/Abbott: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Bristol-Myers Squibb(BMS): Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); GlaxoSmithKlein(GSK): Speaker/Honoraria (Terminated, June 15, 2023); NS Pharma: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Otsuka: Consultant/Advisory Board (Terminated, June 9, 2022); Roche: Speaker/Honoraria (Terminated, November 2, 2022); Sanofi: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated)
Joel Price, MD, MPH, FRCSC: Cook Medical: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)